• TECENTRIQ has a market authorisation in combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, TECENTRIQ, in combination with bevacizumab and the chemotherapy concerned, is indicated only after failure of appropriate targeted therapies.
• The superiority of TECENTRIQ in combination with bevacizumab, paclitaxel and carboplatin compared to bevacizumab, paclitaxel and carboplatinwas demonstrated in terms of progression-free survival assessed by the investigator in an open-label study in the population without EGFR mutations or ALK rearrangements, with a modest absolute increase (+ 1.5 months) and an absolute increase of + 4.5 months overall survival in this same subpopulation on a second interim analysis scheduled in the protocol, with uncertainties relating to these results and the long-term effect.
• The frequency of adverse events having resulted in treatment discontinuation (34% versus 25%) was higher among patients treated with TECENTRIQ + bevacizumab + chemotherapy than among those receiving the combination of bevacizumab + chemotherapy only.

-